Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma

NCT01933815 is registered in ClinicalTrials.gov with Cortice Biosciences, Inc. as lead sponsor.

NCT NCT01933815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01933815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma
Lead sponsor
Cortice Biosciences, Inc.
Phase
Phase 1/2
Overall status
Suspended
Start date
August 31, 2013
Completion date
May 31, 2025
Enrollment
92 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme